TipTraQ Home Sleep Test Study, SHH
Launched by PRANAQ PTE. LTD. · Oct 7, 2024
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Sleep-disordered breathing is a common disease that affects life function and quality of life, and it also imposes a great burden on the public health system. Obstructive sleep apnea accounts for the largest proportion of sleep-disordered breathing, and because of the oriental facial structure, the prevalence of sleep-disordered breathing is relatively high. The current gold standard for diagnosis OSA is polysomnography (PSG). Although the physiological information collected by PSG is complete and detailed, it requires a considerable amount of manpower and medical resources, and changes in ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects from the age of 20 and older that have an indication for an in-lab PSG study.
- Exclusion Criteria:
- • Heart transplant
- • Heart failure, New Youk Heart Association (NYHA) classification III or IV
- • Chronic opioid medication user
- • Devastating severe strokes, with the modified Rankin score (mRS)≥4
- • Tracheostomy
- • Incapable of comprehending and signing the informed consent and questionnaires, including but not limited to subjects with severe Alzheimer's, unconscious by head trauma, or of someone with limited mental capacity
- • Cannot correctly follow the order to use the TipTraQ device
About Pranaq Pte. Ltd.
Pranaq Pte. Ltd. is a forward-thinking clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a commitment to enhancing patient outcomes, Pranaq specializes in the design and execution of clinical trials across various therapeutic areas. The company leverages cutting-edge technologies and a collaborative approach to streamline the trial process, ensuring compliance with regulatory standards while prioritizing participant safety and data integrity. By fostering partnerships with healthcare professionals and institutions, Pranaq aims to contribute significantly to the advancement of medical science and the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Taipei City, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported